PARC/CCL18 is a plasma CC chemokine with increased levels in childhood acute lymphoblastic leukemia.
about
Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processesAttenuation of CXCR4 responses by CCL18 in acute lymphocytic leukemia B cellsSerum level of CC-chemokine ligand 18 is increased in patients with non-small-cell lung cancer and correlates with survival time in adenocarcinomasNovel insights in the regulation of CCL18 secretion by monocytes and dendritic cells via cytokines, toll-like receptors and rheumatoid synovial fluid.Human body fluid proteome analysis.A 7 gene expression score predicts for radiation response in cancer cervixCC-chemokine ligand 18 induces epithelial to mesenchymal transition in lung cancer A549 cells and elevates the invasive potential.An integrated transcriptomic and computational analysis for biomarker identification in gastric cancerInfluence of genetic variation on plasma protein levels in older adults using a multi-analyte panel.CCL18 exhibits a regulatory role through inhibition of receptor and glycosaminoglycan binding.Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease.Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patientsUp-regulation of the chemokine CCL18 by macrophages is a potential immunomodulatory pathway in cutaneous T-cell lymphoma.CCL18/PARC stimulates hematopoiesis in long-term bone marrow cultures indirectly through its effect on monocytes.Circulating levels of the chemokine CCL18 but not CXCL16 are elevated and correlate with disease activity in rheumatoid arthritis.Antimicrobial chemokines.A list of candidate cancer biomarkers for targeted proteomics.Unifying thoracic biomarkers: surfactant protein-D and beyond.The role of systemic inflammatory biomarkers to predict mortality in chronic obstructive pulmonary disease.The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine—the experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation.Glycosaminoglycan Interactions with Chemokines Add Complexity to a Complex System.Upregulation of CC chemokine ligand 18 and downregulation of CX3C chemokine receptor 1 expression in human T-cell leukemia virus type 1-associated lymph node lesions: Results of chemokine and chemokine receptor DNA chip analysis.Incorporation of resident macrophages in engineered tissues: Multiple cell type response to microenvironment controlled macrophage-laden gelatine hydrogels.Hydrogel nanoparticle harvesting of plasma or urine for detecting low abundance proteins.Carcinoma cell-derived chemokines and their presence in oral fluid.Chemokine-Induced Macrophage Polarization in Inflammatory Conditions
P2860
Q24647107-819185FD-CC6D-426F-8E4A-3E72BE914FE4Q28285887-5A686DC0-660B-466A-8A6F-2F88014898BDQ28728826-B1D0F8DA-6487-4EB0-821A-5C3CBF2C8E2EQ33258042-1DCC94FE-4C79-4CE1-88ED-BF7D595FD4E4Q33262623-A974486D-72DE-4037-9491-9D50EC545B07Q33510812-6987B4C1-1EEA-45BF-88DC-B832E22720DBQ34562135-BA7BAF39-D8AD-4DD1-A190-80693AE7A579Q34609329-D1EEC428-0F72-4A13-B1B3-7FCF8C40126CQ34875967-4914D2C4-62A9-4055-B2CB-B3B4AE197C36Q34951532-A2D5E2EE-0464-4974-8164-53DB1EB66788Q35042489-43324785-B5EB-4C11-B0F5-5746175D2DE6Q35053231-7429EB93-5B30-4B2D-BE98-5217F6497DAEQ35168226-9055F6E2-AB9C-4AF8-B523-B6910FDA0457Q35848819-44366E2D-484D-4C9C-AA02-FEAFB1A8F097Q36013933-D0EA9C95-551F-4EC4-B407-EA8DB23CDEE1Q36224086-1010374B-2771-4376-B32E-F453ED0BEFA7Q37277962-70F89EA5-592B-4233-A787-79DBF9D6B200Q37997815-2A6374EA-13F2-4081-9543-0E69211A3EE0Q38077797-7F1882B4-76C9-4E8C-9003-B8712A5E875BQ38083604-B76E44DF-2F1A-4C55-B12A-7D032C060F27Q42366882-C502F4A4-C353-4A5E-8A88-C7DA847423BAQ45399916-9AE7D359-CCEC-4E98-BA4C-D691FACE8048Q48176405-6337B388-0E30-48BD-8BCC-24A46A705711Q49370842-916D8DE3-2B55-42A0-AE80-EEE8AD220EAEQ53308069-89F2EBC8-209A-4ED3-90A9-3102D01AE089Q58758969-6162CF8C-9065-4ADF-B137-45090674C34B
P2860
PARC/CCL18 is a plasma CC chemokine with increased levels in childhood acute lymphoblastic leukemia.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
PARC/CCL18 is a plasma CC chem ...... acute lymphoblastic leukemia.
@ast
PARC/CCL18 is a plasma CC chem ...... acute lymphoblastic leukemia.
@en
type
label
PARC/CCL18 is a plasma CC chem ...... acute lymphoblastic leukemia.
@ast
PARC/CCL18 is a plasma CC chem ...... acute lymphoblastic leukemia.
@en
prefLabel
PARC/CCL18 is a plasma CC chem ...... acute lymphoblastic leukemia.
@ast
PARC/CCL18 is a plasma CC chem ...... acute lymphoblastic leukemia.
@en
P2093
P2860
P50
P1476
PARC/CCL18 is a plasma CC chem ...... acute lymphoblastic leukemia.
@en
P2093
Evemie Schutyser
Jo Van Damme
Klara Gijsbers
Mieke Gouwy
Paul Proost
Yves Benoit
P2860
P304
P356
10.1016/S0002-9440(10)63564-X
P407
P577
2003-11-01T00:00:00Z